Morin, a matrix metalloproteinase 9 inhibitor, attenuates endothelial-to-mesenchymal transition in atherosclerosis by downregulating Notch-1 signaling.
10.1016/j.joim.2024.11.002
- Author:
Yuan HE
1
;
Xiao-Xuan QIN
2
;
Ming-Wei LIU
1
;
Wei SUN
3
,
4
Author Information
1. Department of Cardiology, Jiangsu Provincial People's Hospital, Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.
2. Department of Neurology, Jiangsu Provincial People's Hospital, Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.
3. Department of Cardiology, Jiangsu Provincial People's Hospital, Nanjing Medical University, Nanjing 210029, Jiangsu Province, China. Electronic address: shunwee@
4. com.
- Publication Type:Research Support, Non-U.S. Gov't
- Keywords:
Atherosclerosis;
Endothelial-to-mesenchymal transition;
Matrix metalloproteinase-9;
Morin;
Traditional Chinese medicine
- MeSH:
Flavonoids/pharmacology*;
Animals;
Atherosclerosis/metabolism*;
Humans;
Receptor, Notch1/genetics*;
Signal Transduction/drug effects*;
Matrix Metalloproteinase 9/genetics*;
Human Umbilical Vein Endothelial Cells/drug effects*;
Mice;
Epithelial-Mesenchymal Transition/drug effects*;
Down-Regulation/drug effects*;
Male;
Transforming Growth Factor beta1/genetics*;
Matrix Metalloproteinase Inhibitors/pharmacology*;
Mice, Inbred C57BL;
Flavones
- From:
Journal of Integrative Medicine
2024;22(6):683-695
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:Atherosclerotic cardiovascular disease poses a significant health challenge globally. Recent findings highlight the pivotal role of the endothelial-to-mesenchymal transition (EndMT) in atherosclerosis. Morin is a bioflavonoid mainly extracted from white mulberry, a traditional Chinese herbal medicine with anti-inflammatory and antioxidant properties. This study examines whether morin can alleviate atherosclerosis by suppressing EndMT and seeks to elucidate the underlying mechanism.
METHODS:We induced an in vitro EndMT model in human umbilical vein endothelial cells (HUVECs) by stimulating the cells with transforming growth factor-β1 (TGF-β1) (10 ng/mL) for 48 h. The in vivo experiments were performed in an atherosclerosis model using apolipoprotein E (ApoE)-/- mice fed with a high-fat diet (HFD). Mice in the intervention group were given morin (50 mg/kg) orally for 4 weeks. Molecular docking and microscale thermophoresis were assayed to understand the interactions between morin and matrix metalloproteinase-9 (MMP-9).
RESULTS:Morin inhibited the expression of EndMT markers in a dose-dependent manner in TGF-β1-treated HUVECs. Administering 50 μmol/L morin suppressed the upregulation of MMP-9 and Notch-1 signaling in TGF-β1-induced EndMT. Moreover, the overexpression of MMP-9 activated Notch-1 signaling, thereby reversing morin's inhibitory effect on EndMT. In the HFD-induced atherosclerotic ApoE-/- mice, morin notably reduced aortic intimal hyperplasia and plaque formation by suppressing EndMT. Furthermore, morin demonstrated a strong binding affinity for MMP-9.
CONCLUSION:Morin acts as an MMP-9 inhibitor to disrupt EndMT in atherosclerosis by limiting the activation of Notch-1 signaling. This study underscores morin's potential utility in the development of anti-atherosclerotic medication. Please cite this article as: He Y, Qin XX, Liu MW, Sun W. Morin, a matrix metalloproteinase 9 inhibitor, attenuates endothelial-to-mesenchymal transition in atherosclerosis by downregulating Notch-1 Signaling. J Integr Med. 2024; 22(6): 684-696.
